If the patient presents with a punctate dense diffuse enhancement of the intrahepatic echogenicity, the patient is mostly considered to have hepatic fibrosis. If hepatitis fibrosis is present, the cause of liver fibrosis needs to be further identified, whether it is due to viral hepatitis, autoimmune hepatitis, alcoholic cirrhosis due to frequent alcohol consumption or drug cirrhosis due to long-term drug use; in addition, this condition may also occur in some patients who are frequently strained. Therefore, for patients with liver fibrosis, further blood tests should be taken to identify the cause of the disease and then treat the patient according to the cause, for example, if the patient is suffering from viral hepatitis, we should further check hepatitis B DNA or hepatitis C RNA to see if the virus has replicated. If the virus is replicating and there is a combination of liver function damage, that is, elevated glutathione and glutamic oxalacetic aminotransferase, then antiviral treatment should be actively considered. If the patient has elevated glutathione and glutamic oxalacetic aminotransferase and elevated bilirubin at the same time, the patient should be considered to be suffering from liver damage, and further liver-protective drugs should be infused for liver-protective treatment. In addition, patients should pay attention to more rest during the treatment process, do not stay up late, do not strain, moderate supplementation of vitamin C and other drugs.